
Stridon 35mg Tablet MR
Marketer
Siochem Pharma Pvt Ltd
Salt Composition
Trimetazidine (35mg)
Overview Stridon 35mg Tablet MR
Cardiogard 35mg Extended-Release Tablets are prescribed for angina pectoris, a type of chest pain linked to the heart. This medication works to prevent future angina episodes but isn't effective in treating an attack already in progress. It may be used independently or alongside other cardiac medications. As directed by your physician, consistently take Cardiogard 35mg ER Tablets at the prescribed intervals, with or without food. Dosage frequency is determined by your doctor and may be adjusted based on your response. Continuous use, even when feeling well, is crucial for optimal efficacy and to minimize future cardiac events. Discontinuing treatment may lead to recurring chest pain. Complementing this medication with lifestyle improvements—such as smoking cessation, moderate alcohol consumption, balanced nutrition, regular physical activity, and stress management—can further enhance heart health. Potential side effects include, but are not limited to: lightheadedness, headache, stomach upset, loose stools, dyspepsia, queasiness, vomiting, skin rash, itching, urticaria, and fatigue. Report any persistent or bothersome side effects to your physician immediately. Prior to commencing treatment, inform your doctor about any pre-existing liver or kidney conditions, pregnancy, breastfeeding, and all other concurrent medications.
Primary Ingredients of Stridon 35mg Tablet MR
No text provided. Please provide the text you want me to rephrase.
Uses of Stridon 35mg Tablet MR
Managing Chest Pain Associated with Coronary Artery Disease
Major Benefits of Stridon 35mg Tablet MR:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment schedule. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. Stridon 35mg Modified-Release tablets should be administered with a meal.
Common Side effects of Stridon 35mg Tablet MR:
- Dizziness
- Headache
- Nausea
- Vomiting
- Weakness
- Rash
- Abdominal pain
- Indigestion
- Itching
- Diarrhea
- Hives
How to use Stridon 35mg Tablet MR:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take Stridon 35mg Modified-Release Tablet with a meal.
How Stridon 35mg Tablet MR works:
Stridon 35mg Modified-Release tablets are used to treat angina. They reduce the heart's oxygen demand by altering its energy source from fatty acids to glucose, thus improving cardiac efficiency.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of Stridon 35mg modified-release tablets and alcohol may result in significant somnolence.
PregnancyCONSULT YOUR DOCTOR
Data on Stridon 35mg Tablet MR use in pregnancy is lacking. Seek medical advice from your physician.
Breast feedingCONSULT YOUR DOCTOR
Data on Stridon 35mg Modified-Release Tablet use while breastfeeding is currently unavailable. Seek medical advice from your physician.
DrivingUNSAFE
Taking Stridon 35mg Modified-Release tablets might cause drowsiness, blurred vision, or dizziness. Driving should be avoided if these effects are experienced.
KidneyCAUTION
Patients with kidney impairment should use Stridon 35mg MR tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. Stridon 35mg MR tablets are contraindicated in patients with severe kidney disease.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the use of Stridon 35mg Modified-Release tablets in individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Stridon 35mg Tablet MR :
Should you forget to take a Stridon 35mg MR tablet, administer it immediately upon remembrance. However, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Never take a double dose.
Facts to Know About Stridon 35mg Tablet MR
| Label | Value |
|---|---|
| Chemical Type | Benzylamines |
| Developing Habits | No. |
| Treatment Category | Heart |
| Behavior Class | Fatty acid regulator and sodium channel inhibitor |
